Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its third-quarter report for 2026.
For the first three quarters, the company recorded operating revenue of 1.964 billion yuan, representing a year-on-year increase of 11.51%.
Net profit attributable to shareholders of the parent company reached 220 million yuan, up 10.75% compared with the same period last year.
Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses stood at 198 million yuan, an increase of 14.26% year-on-year.
Basic earnings per share came in at 0.70 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments